Abbott Laboratories’s Stock Price Skyrockets to $123.22, Showing Impressive Growth with a 4.62% Rise

Abbott Laboratories (ABT)

123.22 USD +5.44 (+4.62%) Volume: 13.11M

Abbott Laboratories’s stock price has shown a promising surge, currently trading at 123.22 USD, marking a positive change of +4.62% this trading session with a substantial trading volume of 13.11M. With a year-to-date performance showcasing a gain of +8.94%, ABT’s stock continues to be a viable investment option.

Latest developments on Abbott Laboratories

Abbott Laboratories stock price saw a reversal today as the company’s 2025 sales outlook and diabetes technology shone brightly. With a new price target set at $148.00 by UBS Group, the stock is back in the buy zone following a rating upgrade. Despite missing Q4 sales estimates, Abbott’s 2025 profit forecast met expectations due to strong demand for medical devices. The stock price is expected to rise according to Stifel Nicolaus analysts, indicating positive momentum for the company. Although facing a class-action lawsuit over nutritional claims, Abbott Laboratories remains a key player in the healthcare industry.

Abbott Laboratories on Smartkarma

Analyst coverage of Abbott Laboratories on Smartkarma highlights the company’s strong performance in the third quarter of 2024. According to Baptista Research‘s report, Abbott demonstrated robust results with over 8% organic sales growth and adjusted earnings per share of $1.21. The U.S. Pediatric Nutrition segment showed significant growth, reflecting the company’s effective execution of its strategy across different sectors.

Furthermore, Abbott Laboratories‘ expansion in sensor technology and other innovations was emphasized in another report by Baptista Research. The company’s second quarter 2024 results showcased a strong overall performance, exceeding analyst expectations with over 9% organic sales growth. This led to an increase in full-year guidance, projecting organic sales growth of 9.5% to 10% and adjusted earnings per share between $4.61 and $4.71. Overall, analyst sentiment leans bullish on Abbott Laboratories‘ future prospects based on these research insights.

A look at Abbott Laboratories Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Abbott Laboratories, a company that focuses on health care products and services, has received a mixed outlook based on the Smartkarma Smart Scores. While it scored well in areas such as dividends and momentum, with scores of 4 each, it scored lower in resilience with a score of 2. This suggests that Abbott Laboratories may face challenges in terms of its ability to withstand market fluctuations in the long term. However, with moderate scores in value and growth at 3 each, the company still shows potential for future development and profitability.

Overall, Abbott Laboratories‘ Smartkarma Smart Scores indicate a stable outlook with room for growth and improvement. With a strong focus on pharmaceuticals, nutritional products, diagnostics, and vascular products, the company has a diverse portfolio that positions it well in the healthcare industry. Investors may find Abbott Laboratories to be a reliable choice for dividends and potential market momentum, although they should also consider the company’s resilience in the face of economic uncertainties. As Abbott continues to expand its global reach through affiliates and distributors, its long-term success will depend on how well it navigates industry challenges and opportunities.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma